Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-0-30-253-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$37.14 million
Profitability
Miscellaneous
Employees98
Next Earnings Date7/25/2019 (Estimated)
OptionableNot Optionable
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) announced its quarterly earnings data on Wednesday, April, 3rd. The biotechnology company reported ($0.34) EPS for the quarter. The biotechnology company earned $9.67 million during the quarter. Merus had a negative net margin of 77.61% and a negative return on equity of 40.84%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
5 Wall Street analysts have issued 1-year target prices for Merus' shares. Their predictions range from $16.00 to $35.00. On average, they anticipate Merus' stock price to reach $24.80 in the next year. This suggests a possible upside of 85.1% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Has Merus been receiving favorable news coverage?
News coverage about MRUS stock has been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merus earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Mallinckrodt (MNK), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Theravance Biopharma (TBPH), Epizyme (EPZM), Inflarx (IFRX), Turning Point Therapeutics (TPTX), Eidos Therapeutics (EIDX), Clementia Pharmaceuticals (CMTA), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), Ra Pharmaceuticals (RARX), Homology Medicines (FIXX) and Radius Health (RDUS).
What other stocks do shareholders of Merus own?
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
- Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)
When did Merus IPO?
(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?
Merus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (19.95%), Wellington Management Group LLP (5.01%), Platinum Investment Management Ltd. (0.78%), Morgan Stanley (0.40%), Granite Investment Partners LLC (0.14%) and Oxford Asset Management LLP (0.09%).
Which major investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Acadian Asset Management LLC.
Which major investors are buying Merus stock?
MRUS stock was acquired by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, BVF Inc. IL, Platinum Investment Management Ltd., Renaissance Technologies LLC, Morgan Stanley, Wellington Management Group LLP, BlackRock Inc. and JPMorgan Chase & Co..
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $13.40.
How big of a company is Merus?
Merus has a market capitalization of $304.86 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
